The clinical profile, management, and outcome of febrile neutropenia in acute myeloid leukemia from resource constraint settings. (August 2021)

• Record Type: Journal Article
• Authors: Mishra, Kundan; Kumar, Suman; Ninawe, Sandeep; Bahl, Rajat; Meshram, Ashok; Singh, Kanwaljeet; Jandial, Aditya; Sahu, Kamal Kant; Sandal, Rajeev; Khera, Sanjeev; Yanamandra, Uday; Khurana, Harshit; Kumar, Rajiv; Kapoor, Rajan; Sharma, Sanjeevan; Singh, Jasjit; Das, Satyaranjan; Ahuja, Ankur; Somasundaram, Venkateshan; Chaterjee, Tathagat
• Is Part Of: Therapeutic advances in infectious disease. Volume 8(2021)
• Publication Date: 2021-08
• Subjects: acute myeloid leukemia -- febrile neutropenia -- resource constraint settings; Communicable diseases -- Treatment -- Periodicals; Infection -- Treatment -- Periodicals; 616.905
• DOI: 10.1177/20499361211036592
• Languages: English
• ISSNs: 2049-9361

Abstract

Introduction: Acute myeloid leukemia (AML) is the commonest leukemia in adults. Mortality in thew first 30-days ranges from 6% to 43%, while infections account for 30–66% of early deaths. We aim to present our experience of infections in newly-diagnosed AML. Method: This prospective, observational study, was undertaken at a tertiary care hospital in Northern India. Patients with confirmed AML (bone marrow morphology and flow cytometry) and who had developed febrile neutropenia (FN), were included. Result: A total of fifty-five patients were included in the study. The median age of the patients was 47.1 years (12–71) and 28 (50.9%) were males. Fever (33, 60%) was the commonest presentation at the time of diagnosis. One or more comorbid conditions were present in 20 patients (36.36%). Infection at presentation was detected in 17 patients (30.9%). The mean duration to develop febrile neutropenia since the start of therapy was 11.24 days. With each ten-thousand increase in white blood cell (WBC) count, the mean number of days of FN development decreased by 0.35 days ( p = 0.029). Clinical and/or radiological localization was possible in 23 patients (41.81%). Thirty-four blood samples (34/242, 14.04%) from 26 patients (26/55, 47.3%) isolated one or more organisms. Gram negative bacilli (GNB) were isolated in 24 (70.58%) samples. Burkholderia cepacia (8/34, 23.52%) was the commonest organism. The number of days required to develop febrile neutropenia was inversely associated with overall survival (OS). However, when compared, there was no statistically significant difference in OS between patients developing fever on day-10 and day-25 ( p = 0.063). Thirteen patients (23.63%) died during the study period. Discussion: Low percentage of blood culture positivity and high incidence of MDR organisms are a matter of concern. Days to develop febrile neutropenia were inversely associated with overall survival (OS), emphasizing the importance of preventive measures against infections. Conclusion: Infections continues to be a major cause of morbidity and mortality among AML patients.